Company research
ASSEMBLY BIOSCIENCES, INC.
CIK 1426800Updated Sep 26, 2026
SecurityASMB · NASDAQ · equity
Name history
VENTRUS BIOSCIENCES INC · through Jul 11, 2014
ASMB price & chart
Loading TradingView…
NASDAQ:ASMB on TradingView ↗About the company
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesvirus, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV). For more information, visit assemblybio.com.
In the news
Assembly Biosciences Announces Upcoming Investor Conference Presentations ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 257,590,000Source | 119,168,000Source | 136,823,000Source | 101,794,000Source |
| Property, Plant and Equipment, NetUSD | 221,000Source | 284,000Source | 385,000Source | 743,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 58,450,000Source | 38,344,000Source | 19,841,000Source | 52,418,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 974,000Source | 0Source | 43,000Source | 944,000Source |
| Assets, CurrentUSD | 254,549,000Source | 115,503,000Source | 133,787,000Source | 96,967,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,469,000Source | 3,424,000Source | 3,497,000Source | 4,413,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,508,000Source | 3,069,000Source | 2,339,000Source | 3,195,000Source |
| Other Assets, NoncurrentUSD | 312,000Source | 312,000Source | 312,000Source | 889,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 50,839,000Source | 85,809,000Source | 95,726,000Source | 19,130,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 16,000Source | 7,000Source | 5,000Source | 49,000Source |
| Retained Earnings (Accumulated Deficit)USD | -832,047,000Source | -825,925,000Source | -785,748,000Source | -724,520,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -41,000Source | -211,000Source | -81,000Source | -803,000Source |
| Stockholders' Equity Attributable to ParentUSD | 206,751,000Source | 33,359,000Source | 41,097,000Source | 82,664,000Source |
| Additional Paid in Capital, Common StockUSD | 1,038,823,000Source | 859,488,000Source | 826,921,000Source | 807,938,000Source |
| Liabilities and EquityUSD | 257,590,000Source | 119,168,000Source | 136,823,000Source | 101,794,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 48,780,000Source | 47,803,000Source | 39,225,000Source | 16,296,000Source |
| Operating Lease, Liability, CurrentUSD | 569,000Source | 461,000Source | 1,220,000Source | 3,364,000Source |
| Accounts Payable, CurrentUSD | 1,171,000Source | 585,000Source | 461,000Source | 2,493,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,059,000Source | 2,628,000Source | 1,122,000Source | 101,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,749,000Source | 6,862,000Source | 5,744,000Source | 7,317,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 248,100,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -6,122,000Source | -40,177,000Source | -61,228,000Source | -93,092,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 129,000Source | 129,000Source | 450,000Source | 498,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,677,000Source | 3,120,000Source | 5,119,000Source | 6,593,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 974,000Source | -43,000Source | -901,000Source | 608,000Source |
| Increase (Decrease) in Accounts PayableUSD | 586,000Source | 124,000Source | -2,032,000Source | -166,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -41,093,000Source | -51,117,000Source | 22,743,000Source | -84,463,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -113,468,000Source | 40,171,000Source | -69,138,000Source | 90,640,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 66,000Source | 28,000Source | 255,000Source | 102,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 174,667,000Source | 29,449,000Source | 13,818,000Source | 614,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 20,106,000Source | 18,503,000Source | -32,577,000Source | 6,791,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | — | 421,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 4,677,000Source | 3,120,000Source | 5,119,000Source | 6,593,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 248,100,000Source | — | — | — |
| Debt Securities, Realized Gain (Loss)USD | 3,000Source | — | — | — |
| DepreciationUSD | — | — | 500,000Source | 500,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 0Source | -139,000Source | 0Source |
| General and Administrative ExpenseUSD | 19,608,000Source | 18,007,000Source | 22,909,000Source | 24,134,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | 330,000Source | 33,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -6,122,000Source | -40,177,000Source | -61,228,000Source | -93,092,000Source |
| Nonoperating Income (Expense)USD | 5,996,000Source | 5,573,000Source | 3,451,000Source | 1,022,000Source |
| Operating ExpensesUSD | 84,421,000Source | 73,940,000Source | 71,809,000Source | 94,114,000Source |
| Proceeds from Issuance of Common StockUSD | 1,922,000Source | 2,030,000Source | 4,546,000Source | 325,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 116,432,000Source | 130,700,000Source | 65,015,000Source | 88,000,000Source |
| Proceeds from Stock Options ExercisedUSD | 125,000Source | 5,000Source | — | — |
| Realized Investment Gains (Losses)USD | — | 0Source | 0Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | 28,520,000Source | 7,163,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 72,303,000Source | — | — | — |
| Operating Income (Loss)USD | -12,118,000Source | -45,420,000Source | -64,646,000Source | -94,114,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -6,122,000Source | -39,847,000Source | -61,195,000Source | -93,092,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 330,000Source | 33,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -6,122,000Source | -40,177,000Source | -61,228,000Source | -93,092,000Source |
| Earnings Per Share, BasicUSD per share | -0.55Source | -6.69Source | -13.38Source | -1.92Source |
| Earnings Per Share, DilutedUSD per share | -0.55Source | -6.69Source | -13.38Source | -1.92Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 11,210,934Source | 6,004,560Source | 4,577,371Source | 48,409,265Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 11,210,934Source | 6,004,560Source | 4,577,371Source | 48,409,265Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | 330,000Source | 33,000Source | — |
| Debt Securities, Realized Gain (Loss)USD | 3,000Source | — | — | — |
| General and Administrative ExpenseUSD | 19,608,000Source | 18,007,000Source | 22,909,000Source | 24,134,000Source |
| Interest Income, OtherUSD | 5,996,000Source | 5,573,000Source | 3,451,000Source | 1,022,000Source |
| Nonoperating Income (Expense)USD | 5,996,000Source | 5,573,000Source | 3,451,000Source | 1,022,000Source |
| Operating ExpensesUSD | 84,421,000Source | 73,940,000Source | 71,809,000Source | 94,114,000Source |
| Realized Investment Gains (Losses)USD | — | 0Source | 0Source | — |
| Research and Development ExpenseUSD | 64,813,000Source | 55,933,000Source | 48,900,000Source | 69,980,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | 28,520,000Source | 7,163,000Source | — |
Filing attachments
asmb-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 asmb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates - Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) - - Completed $115 million gross financing to support advancement of pipeline programs through key development milestones - - GS-1179 (formerly ABI-1179) selected to advance in HSV HPI progra…
Read attachment ↗asmb-ex4_1.htm · 8-K · 2026-05-26
EX-4.1 3 asmb-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT ASSEMBLY BIOSCIENCES, INC. Warrant Shares: [______] Initial Exercise Date: May [__], 2026 THIS PRE-FUNDED WARRANT (the “Warrant”) certifies that, for value received, [______] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”), to subscribe for and purchase fro…
Read attachment ↗asmb-ex99_1.htm · 8-K · 2026-05-26
EX-99.1 5 asmb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants SOUTH SAN FRANCISCO, Calif. - May 22, 2026 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an aggregate of 3,358,602 shares of common stock at an of…
Read attachment ↗asmb-ex99_2.htm · 8-K · 2026-05-26
EX-99.2 6 asmb-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif. - May 26, 2026 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten reg…
Read attachment ↗asmb-ex99_1.htm · 8-K · 2026-05-22
EX-99.1 2 asmb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases - Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 - - Builds on completed Phase 1a study and ongoing development in HDV - SOUTH SAN FRANCISCO, Calif. - May 22, 2026 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targe…
Read attachment ↗asmb-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 asmb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes - - Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 - SOUTH SAN FRANCISCO, Calif. - May 7, 2026 - Assembly Bi…
Read attachment ↗